GRIFOLS

Grifols signs renewable energy purchase agreement with ENGIE to cover more than half of its electricity consumption in Spain

- ***The company will receive a total of 40 GWh of renewable energy annually over the next 10 years, further advancing its decarbonization strategy and contributing to Spain's energy transition***
- ***The purchase of this clean energy is expected to avoid approximately 8,000 metric tons of CO_2 emissions annually***
- ***The agreement represents another step forward in the implementation of Grifols' 2025–2027 Sustainability Plan and contributes to the achievement of the company's 2030 Agenda and decarbonization strategy goals***

Barcelona, Spain, September 16, 2026 – Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading producer of plasma-derived medicines, has entered into a renewable power purchase agreement (PPA) with ENGIE, a global leader in low-carbon energy and services, to purchase a total of 40 GWh of renewable energy annually over the next 10 years. The agreement, which will run from 2027 through 2037, complements Grifols' existing renewable electricity supply and will enable the company to cover 66% of its electricity demand in Spain from renewable sources.

The electricity supplied to Grifols will come from new solar photovoltaic and wind facilities located in Spain. By sourcing electricity from these facilities, the company is expected to avoid approximately 8,000 metric tons of CO_2 emissions annually.

Through this long-term renewable PPA, Grifols will benefit from a stable and predictable supply of renewable electricity, while ENGIE will commit to supplying power generated by the contracted facilities throughout the term of the agreement. The development of these renewable energy facilities will help strengthen Spain's power generation capacity and support the country's energy transition.

"Grifols' commitment to the environment, reflected in its decarbonization targets and efforts to improve the energy efficiency of its facilities, actively contributes to the development of new wind and solar power plants that will strengthen Spain's electricity system through the agreement reached with ENGIE," said **Daniel Fleta**, **Chief Industrial Services Officer** at Grifols.

Net zero emissions by 2050

The agreement between Grifols and ENGIE supports the company's commitment to reduce its absolute Scope 1 and 2 greenhouse gas (GHG) emissions by 42% and its Scope 3 emissions by 25% by 2030, compared with a 2022 baseline. The ultimate goal is to achieve net zero emissions by 2050.

A key element of this effort is the company's commitment to expanding and promoting the use of renewable energy. In line with the goals established in its sustainability strategy, Grifols aims for 100% of the electricity it consumes to come from renewable sources by 2030. This commitment includes the purchase of green energy and the development of new power generation facilities, complemented by renewable electricity supply agreements.

Grifols will also build a new production facility in Lliçà de Vall that will operate entirely on renewable electricity. At the same time, the company will implement smart resource monitoring and management systems across a highly digitalized campus to optimize energy and water consumption and minimize unnecessary use, supporting greater energy efficiency. The application of circular economy best practices will ensure that materials are reused throughout their life cycle. Construction of the facility is expected to begin this year, with operations scheduled to start in 2030.

The renewable power purchase agreement is part of Grifols' 2025–2027 Sustainability Plan and represents another step forward in the implementation of the company's sustainability roadmap. By the end of 2025, Grifols had already achieved approximately 60% of its goal of sourcing 100% of its electricity from renewable sources by 2030, further consolidating progress toward the commitments outlined in its 2030 Agenda. As part of this commitment, the company continues to advance the development of its Climate Transition and Decarbonization Plan, which will establish the roadmap for accelerating emissions reductions and progressing toward the goal of net zero emissions by 2050.

Grifols' commitment to reducing its environmental footprint is also reflected in prestigious sustainability rankings, including the 2025 EcoVadis assessment, in which the company received the highest distinction, Platinum, with a score of 86 out of 100. This recognition further reinforces Grifols' position as a global sustainability leader, following its recognition as one of the world's most sustainable biotechnology companies by the Dow Jones Best-in-Class Indices.

About Grifols

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. A leader in essential plasma-derived medicines and transfusion medicine, the company develops, produces and provides innovative healthcare services and solutions in more than 110 countries.

Patient needs and Grifols' ever-growing knowledge of many chronic, rare and prevalent conditions, at times life-threatening, drive the company's innovation in both plasma and other biopharmaceuticals to enhance quality of life. Grifols focuses on treating conditions centered on six core therapeutic areas: immunology, neurology, pulmonology, hematology, hepatology and intensive care.

A pioneer in the plasma industry, Grifols continues to grow its network of donation centers, the world's most diversified with more than 400 across North America, Europe, Africa and the Middle East, and China.

As a recognized leader in transfusion medicine, Grifols offers a comprehensive portfolio of solutions designed to enhance safety from donation to transfusion, in addition to clinical diagnostic technologies. It provides high-quality biological supplies for life-science research, clinical trials and for manufacturing pharmaceutical and diagnostic products. The company also supplies tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care.

Grifols, with more than 25,000 employees in more than 30 countries and regions, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership.

The company's class A shares are listed on the Spanish Stock Exchange, where they are part of the IBEX-35 (MCE:GRF). Grifols non- voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ through ADRs (NASDAQ:GRFS).

For more information about Grifols, please visit www.grifols.com.

MEDIA CONTACTS:

Grifols Press Office
media@grifols.com
Phone: +34 93 571 00 02

INVESTORS:

Investor Relations & Sustainability
investors@grifols.com – inversores@grifols.com
sustainability@grifols.com – sostenibilidad@grifols.com
Phone: +34 93 571 02 21

Contacto de prensa ENGIE
Carolina Ubis

Tel. +34 689 779 582

LEGAL DISCLAIMER

The facts and figures contained in this report that do not refer to historical data are 'projections and future hypotheses'. Words and expressions such as 'believe', 'expect', 'anticipate', 'predict', 'hope', 'intend', 'should', 'will try to achieve', 'is estimated', 'future' and similar expressions, insofar as they refer to the Grifols group, are used to identify future projections and hypotheses. These expressions reflect the assumptions, hypotheses, expectations and predictions of the management team at the time of writing this report, and these are subject to a series of factors that mean that the real results may be materially different. The future results of the Grifols group could be affected by events related to its own activities, such as shortages of supplies of raw materials for the manufacture of its products, the appearance on the market of competing products, or changes in the regulatory framework of the markets in which it operates, among others. At the date of preparation of this report, the Grifols group has adopted the necessary measures to mitigate the foreseeable impact of these events. Grifols, S.A. assumes no obligation to publicly report, revise or update the projections or future hypotheses to adapt them to facts or circumstances after the date of writing of this report, except when expressly required by applicable legislation. This document does not constitute an offer or invitation to purchase or subscribe shares in accordance with the provisions of Law 6/2023, of 17 March, on the Securities Markets and Investment Services, and any regulations implementing said legislation. Furthermore, this document does not constitute an offer to purchase, sell or exchange, or a solicitation of an offer to purchase, sell or exchange any securities, or a solicitation of any vote or approval in any other jurisdiction. The information contained in this document has not been verified or revised by the external auditors of the Grifols group.